Last Updated: 06/11/2024
Deciphering P. falciparum artemisinin resistance in Bangladesh: a genotypic-phenotypic evaluation of Kelch13 dependent and independent determinants
Objectives
This project aims to:
- Perform whole-genome sequencing of in vitro evolved K13 independent artemisinin resistance (ART-R) in recent Chittagong Hill Tracts (CHTs) isolates; in parallel determine the drug sensitivities and genomic sequences of parasites recently isolated from CHT patients and functionally validate top candidate genes by CRISPR-Cas9 editing.
- Perform preemptive resistance and fitness cost analysis of major K13 mutations in the K13 independent ART resistant and ART sensitive CHT genetic backgrounds, to determine if these “unknown factors” assist the resistance potential and sustainability of these K13 mutations.
Malaria control and elimination face significant challenges due to drug resistance, particularly to the current front-line artemisinin-based combination therapy in the Greater Mekong Region, to artemisinin (ART) derivatives in Myanmar and now disturbingly in eastern Africa where most serious falciparum malaria cases are concentrated. To ensure the continued effectiveness of ART and its partner drugs, early detection and characterization of resistance, robust surveillance and subsequent isolation are required. World-wide clinical and molecular surveillance of artemisinin resistance (ART-R) relies on southeast Asian characteristics of longer parasite clearance times from patients and genotyping for mutations in the most common ART resistant gene, k13 (a gene on chromosome 13 coding for a kelch domain protein, K13). The Chittagong Hill Tracts (CHTs) in Bangladesh borders Myanmar, and is a forested, hilly and remote region that is endemic to 90% of the country’s malaria. Recent clinical clearance and in vitro assays not only in the CHTs but also in Africa demonstrate that although combination treatment remains efficacious in infected patients, a cohort of the field isolates display in vitro low-moderate ART-R with no K13 mutations. This suggests that clones with partial ART-R exist and are going undetected by patient parasite clearance studies and molecular surveillance. Proactive analysis of the impact of these molecular determinants will be critical to characterize resistance before the problem is widespread in these regions in the pre-elimination era. The hypothesis is that 1) Clinical ART resistant mutations can be predicted from in vitro generated mutants in isolates from the same spatiotemporal space. 2) ART sensitivity is changing in the CHTs with continued use of artemisinin combination therapy since 2004. The initial low-moderate ART-R mediated by causal K13 independent mutations will be an optimal platform for highly resistant and highly fit K13 mutations to arise and spread. These hypotheses will be tested with two specific aims. Together, this study will provide a comprehensive view of the complex emerging ART-R with a broader applicability to similar scenarios in Eastern Africa.
May 2024 — Mar 2026
$195,625
Related Resources
